249 related articles for article (PubMed ID: 26319513)
1. Identification of putative drug targets in Vancomycin-resistant Staphylococcus aureus (VRSA) using computer aided protein data analysis.
Hasan MA; Khan MA; Sharmin T; Hasan Mazumder MH; Chowdhury AS
Gene; 2016 Jan; 575(1):132-43. PubMed ID: 26319513
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of potential drug targets by subtractive genome analyses of methicillin resistant Staphylococcus aureus.
Uddin R; Saeed K
Comput Biol Chem; 2014 Feb; 48():55-63. PubMed ID: 24361957
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States.
Kos VN; Desjardins CA; Griggs A; Cerqueira G; Van Tonder A; Holden MT; Godfrey P; Palmer KL; Bodi K; Mongodin EF; Wortman J; Feldgarden M; Lawley T; Gill SR; Haas BJ; Birren B; Gilmore MS
mBio; 2012; 3(3):. PubMed ID: 22617140
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential drug targets by subtractive genome analysis of Bacillus anthracis A0248: An in silico approach.
Rahman A; Noore S; Hasan A; Ullah R; Rahman H; Hossain A; Ali Y; Islam S
Comput Biol Chem; 2014 Oct; 52():66-72. PubMed ID: 25254941
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Oct; 51(40):902. PubMed ID: 12418544
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.
Hiramatsu K
Lancet Infect Dis; 2001 Oct; 1(3):147-55. PubMed ID: 11871491
[TBL] [Abstract][Full Text] [Related]
7. Metabolic pathway analysis approach: identification of novel therapeutic target against methicillin resistant Staphylococcus aureus.
Uddin R; Saeed K; Khan W; Azam SS; Wadood A
Gene; 2015 Feb; 556(2):213-26. PubMed ID: 25436466
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
9. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
10. Genomic organization of a vancomycin-resistant Staphylococcus aureus.
Mirani ZA; Jamil N
J Coll Physicians Surg Pak; 2013 Feb; 23(2):107-11. PubMed ID: 23374512
[TBL] [Abstract][Full Text] [Related]
11. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm.
Weigel LM; Donlan RM; Shin DH; Jensen B; Clark NC; McDougal LK; Zhu W; Musser KA; Thompson J; Kohlerschmidt D; Dumas N; Limberger RJ; Patel JB
Antimicrob Agents Chemother; 2007 Jan; 51(1):231-8. PubMed ID: 17074796
[TBL] [Abstract][Full Text] [Related]
12. Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11.
Hosen MI; Tanmoy AM; Mahbuba DA; Salma U; Nazim M; Islam MT; Akhteruzzaman S
Interdiscip Sci; 2014 Mar; 6(1):48-56. PubMed ID: 24464704
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Saravolatz LD; Pawlak J; Johnson LB
Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
[TBL] [Abstract][Full Text] [Related]
14. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center.
Bozdogan B; Ednie L; Credito K; Kosowska K; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4762-5. PubMed ID: 15561854
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.
Sievert DM; Rudrik JT; Patel JB; McDonald LC; Wilkins MJ; Hageman JC
Clin Infect Dis; 2008 Mar; 46(5):668-74. PubMed ID: 18257700
[TBL] [Abstract][Full Text] [Related]
16. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
Hiramatsu K; Aritaka N; Hanaki H; Kawasaki S; Hosoda Y; Hori S; Fukuchi Y; Kobayashi I
Lancet; 1997 Dec; 350(9092):1670-3. PubMed ID: 9400512
[TBL] [Abstract][Full Text] [Related]
17. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis of vancomycin-resistant Staphylococcus aureus VRS3b and its comparison with other VRSA isolates.
Panthee S; Hamamoto H; Paudel A; Sekimizu K
Drug Discov Ther; 2017 May; 11(2):78-83. PubMed ID: 28458299
[TBL] [Abstract][Full Text] [Related]
19. Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50.
Avison MB; Bennett PM; Howe RA; Walsh TR
J Antimicrob Chemother; 2002 Feb; 49(2):255-60. PubMed ID: 11815565
[TBL] [Abstract][Full Text] [Related]
20. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran.
Aligholi M; Emaneini M; Jabalameli F; Shahsavan S; Dabiri H; Sedaght H
Med Princ Pract; 2008; 17(5):432-4. PubMed ID: 18685289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
